INDUSTRY OVERVIEW
The Point of Care Molecular Diagnosis is Growing at 18% and is expected to reach 7Billion by 2031. Below mentioned are some of the dynamics shaping the Point of Care Molecular Diagnosis .Point of Care Molecular Diagnosis Market Size in (USD Billion) CAGR Growth Rate 18%
| Study Period | 2019-2031 |
| Market Size (2023): | 3Billion |
| Market Size (2031): | 7Billion |
| CAGR (2023 - 2031): | 18% |
| Fastest Growing Region | Asia Pacific |
| Domination Region | North America |
www.www.htfmarketinsights.com
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading to much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Microfluidics And Other Instrumentation Technologies That Allow For The Creation Of Low-Cost Platforms And Tests
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Market Competition
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Healthcare
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- In Resource-Constrained Environments
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- PCR
- Lateral Flow
- Biosensors
- Immunoassays
Point of Care Molecular Diagnosis Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Healthcare
- Hospitals
- Diagnostics
- Research
- Emergency Care
Point of Care Molecular Diagnosis Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Roche (Switzerland)
- Abbott Laboratories (United States)
- Biomerieux (France)
- Danaher (United States)
- Roche diagnostics (Switzerland)
- Meridian biosciences (United States)
- Quidel (United States)
- Sanofi (France)
- Merck (United States)
- Johnson and Johnson (United States)
Point of Care Molecular Diagnosis Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2023 |
|
Based Year Market Size (2023) |
3Billion |
|
Historical Period |
2019 to 2023 |
|
CAGR (2023 to 2031) |
18% |
|
Forecast Period |
2023 to 2031 |
|
Forecasted Period Market Size (2031) |
7Billion |
|
Scope of the Report |
PCR, Lateral Flow, Biosensors, Immunoassays, Healthcare, Hospitals, Diagnostics, Research, Emergency Care. Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States) , Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States), Johnson and Johnson (United States) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Point of Care Molecular Diagnosis - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Point of Care Molecular Diagnosis Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Point of Care Molecular Diagnosis Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Point of Care Molecular Diagnosis Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests
-
3.2 Available Opportunities
- 3.2.1 In Resource-Constrained Environments
- 3.2.2 Molecular POCT is Becoming Increasingly Beneficial
-
3.3 Influencing Trends
- 3.3.1 Healthcare
- 3.3.2 diagnostics
-
3.4 Challenges
- 3.4.1 Market competition
- 3.4.2 technological innovation
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Point of Care Molecular Diagnosis Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Point of Care Molecular Diagnosis Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
Chapter 5: Point of Care Molecular Diagnosis : Competition Benchmarking & Performance Evaluation
- 5.1 Global Point of Care Molecular Diagnosis Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Point of Care Molecular Diagnosis Revenue 2023
- 5.3 Global Point of Care Molecular Diagnosis Sales Volume by Manufacturers (2023)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 5C’s Analysis
- 5.6 Ansoff Matrix
Chapter 6: Global Point of Care Molecular Diagnosis Market: Company Profiles
- 6.1 Roche (Switzerland)
- 6.1.1 Roche (Switzerland) Company Overview
- 6.1.2 Roche (Switzerland) Product/Service Portfolio & Specifications
- 6.1.3 Roche (Switzerland) Key Financial Metrics
- 6.1.4 Roche (Switzerland) SWOT Analysis
- 6.1.5 Roche (Switzerland) Development Activities
- 6.2 Abbott Laboratories (United States)
- 6.3 Biomerieux (France)
- 6.4 Danaher (United States)
- 6.5 Roche Diagnostics (Switzerland)
- 6.6 Meridian Biosciences (United States)
- 6.7 Quidel (United States)
- 6.8 Sanofi (France)
- 6.9 Merck (United States)
- 6.10 Johnson And Johnson (United States)
- 6.11
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Point of Care Molecular Diagnosis by Type & Application (2019-2031)
-
7.1 Global Point of Care Molecular Diagnosis Market Revenue Analysis (USD Million) by Type (2019-2023)
- 7.1.1 PCR
- 7.1.2 Lateral Flow
- 7.1.3 Biosensors
- 7.1.4 Immunoassays
- 7.1.5 CRISPR
-
7.2 Global Point of Care Molecular Diagnosis Market Revenue Analysis (USD Million) by Application (2019-2023)
- 7.2.1 Healthcare
- 7.2.2 Hospitals
- 7.2.3 Diagnostics
- 7.2.4 Research
- 7.2.5 Emergency Care
- 7.3 Global Point of Care Molecular Diagnosis Market Revenue Analysis (USD Million) by Type (2023-2031)
- 7.4 Global Point of Care Molecular Diagnosis Market Revenue Analysis (USD Million) by Application (2023-2031)
Chapter 8 : North America Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 8.1 North America Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 8.2.1 PCR
- 8.2.2 Lateral Flow
- 8.2.3 Biosensors
- 8.2.4 Immunoassays
- 8.2.5 CRISPR
-
8.3 North America Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 8.3.1 Healthcare
- 8.3.2 Hospitals
- 8.3.3 Diagnostics
- 8.3.4 Research
- 8.3.5 Emergency Care
- 8.4 North America Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 8.5 North America Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 8.6 North America Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 9.1 LATAM Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 9.2.1 PCR
- 9.2.2 Lateral Flow
- 9.2.3 Biosensors
- 9.2.4 Immunoassays
- 9.2.5 CRISPR
-
9.3 LATAM Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 9.3.1 Healthcare
- 9.3.2 Hospitals
- 9.3.3 Diagnostics
- 9.3.4 Research
- 9.3.5 Emergency Care
- 9.4 LATAM Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 9.5 LATAM Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 9.6 LATAM Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 10 : West Europe Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 10.1 West Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 10.2.1 PCR
- 10.2.2 Lateral Flow
- 10.2.3 Biosensors
- 10.2.4 Immunoassays
- 10.2.5 CRISPR
-
10.3 West Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 10.3.1 Healthcare
- 10.3.2 Hospitals
- 10.3.3 Diagnostics
- 10.3.4 Research
- 10.3.5 Emergency Care
- 10.4 West Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 10.5 West Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 10.6 West Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 11 : Central & Eastern Europe Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 11.2.1 PCR
- 11.2.2 Lateral Flow
- 11.2.3 Biosensors
- 11.2.4 Immunoassays
- 11.2.5 CRISPR
-
11.3 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 11.3.1 Healthcare
- 11.3.2 Hospitals
- 11.3.3 Diagnostics
- 11.3.4 Research
- 11.3.5 Emergency Care
- 11.4 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 11.5 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 11.6 Central & Eastern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 12 : Northern Europe Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 12.2.1 PCR
- 12.2.2 Lateral Flow
- 12.2.3 Biosensors
- 12.2.4 Immunoassays
- 12.2.5 CRISPR
-
12.3 Northern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 12.3.1 Healthcare
- 12.3.2 Hospitals
- 12.3.3 Diagnostics
- 12.3.4 Research
- 12.3.5 Emergency Care
- 12.4 Northern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 12.5 Northern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 12.6 Northern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 13 : Southern Europe Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 13.2.1 PCR
- 13.2.2 Lateral Flow
- 13.2.3 Biosensors
- 13.2.4 Immunoassays
- 13.2.5 CRISPR
-
13.3 Southern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 13.3.1 Healthcare
- 13.3.2 Hospitals
- 13.3.3 Diagnostics
- 13.3.4 Research
- 13.3.5 Emergency Care
- 13.4 Southern Europe Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 13.5 Southern Europe Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 13.6 Southern Europe Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 14 : East Asia Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 14.1 East Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 14.2.1 PCR
- 14.2.2 Lateral Flow
- 14.2.3 Biosensors
- 14.2.4 Immunoassays
- 14.2.5 CRISPR
-
14.3 East Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 14.3.1 Healthcare
- 14.3.2 Hospitals
- 14.3.3 Diagnostics
- 14.3.4 Research
- 14.3.5 Emergency Care
- 14.4 East Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 14.5 East Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 14.6 East Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 15 : Southeast Asia Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 15.2.1 PCR
- 15.2.2 Lateral Flow
- 15.2.3 Biosensors
- 15.2.4 Immunoassays
- 15.2.5 CRISPR
-
15.3 Southeast Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 15.3.1 Healthcare
- 15.3.2 Hospitals
- 15.3.3 Diagnostics
- 15.3.4 Research
- 15.3.5 Emergency Care
- 15.4 Southeast Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 15.5 Southeast Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 15.6 Southeast Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 16 : South Asia Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 16.1 South Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 16.2.1 PCR
- 16.2.2 Lateral Flow
- 16.2.3 Biosensors
- 16.2.4 Immunoassays
- 16.2.5 CRISPR
-
16.3 South Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 16.3.1 Healthcare
- 16.3.2 Hospitals
- 16.3.3 Diagnostics
- 16.3.4 Research
- 16.3.5 Emergency Care
- 16.4 South Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 16.5 South Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 16.6 South Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 17 : Central Asia Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 17.1 Central Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 17.2.1 PCR
- 17.2.2 Lateral Flow
- 17.2.3 Biosensors
- 17.2.4 Immunoassays
- 17.2.5 CRISPR
-
17.3 Central Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 17.3.1 Healthcare
- 17.3.2 Hospitals
- 17.3.3 Diagnostics
- 17.3.4 Research
- 17.3.5 Emergency Care
- 17.4 Central Asia Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 17.5 Central Asia Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 17.6 Central Asia Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 18 : Oceania Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 18.1 Oceania Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 18.2.1 PCR
- 18.2.2 Lateral Flow
- 18.2.3 Biosensors
- 18.2.4 Immunoassays
- 18.2.5 CRISPR
-
18.3 Oceania Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 18.3.1 Healthcare
- 18.3.2 Hospitals
- 18.3.3 Diagnostics
- 18.3.4 Research
- 18.3.5 Emergency Care
- 18.4 Oceania Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 18.5 Oceania Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 18.6 Oceania Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 19 : MEA Point of Care Molecular Diagnosis Market Breakdown by Country, Type & Application
- 19.1 MEA Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 19.2.1 PCR
- 19.2.2 Lateral Flow
- 19.2.3 Biosensors
- 19.2.4 Immunoassays
- 19.2.5 CRISPR
-
19.3 MEA Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 19.3.1 Healthcare
- 19.3.2 Hospitals
- 19.3.3 Diagnostics
- 19.3.4 Research
- 19.3.5 Emergency Care
- 19.4 MEA Point of Care Molecular Diagnosis Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 19.5 MEA Point of Care Molecular Diagnosis Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 19.6 MEA Point of Care Molecular Diagnosis Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Point of Care Molecular Diagnosis market is expected to see value worth 3Billion in 2023.
According to the report,the Point of Care Molecular Diagnosis Industry size is projected to reach 7Billion, exhibiting a CAGR of 18% by 2031.
The changing dynamics and trends such as Healthcare, Diagnostics are seen as major Game Changer in Global Point of Care Molecular Diagnosis Market.
- Microfluidics And Other Instrumentation Technologies That Allow For The Creation Of Low-Cost Platforms And Tests
Some of the major roadblocks that industry players have identified are Market Competition, Technological Innovation.
Some of the opportunities that Analyst at HTF MI have identified in Point of Care Molecular Diagnosis Market are:
- In Resource-Constrained Environments
- Molecular POCT Is Becoming Increasingly Beneficial
Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States) , Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States), Johnson and Johnson (United States), are the major operating companies profiled in Point of Care Molecular Diagnosis market study.
The Global Point of Care Molecular Diagnosis Market Study is Broken down by applications such as Healthcare, Hospitals, Diagnostics, Research, Emergency Care.
The Global Point of Care Molecular Diagnosis Market Study is segmented by PCR, Lateral Flow, Biosensors, Immunoassays, CRISPR.
The Global Point of Care Molecular Diagnosis Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2019 - 2023; Base year: 2023; Forecast period: 2025 to 2031
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading to much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.
